ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Response Criteria"

  • Abstract Number: 1259 • ACR Convergence 2021

    Association of SLE Responder Index (SRI) Attainment and Long-term Clinical Outcomes

    Kathryn Connelly1, Rangi Kandane-Rathnayake1, Alberta Hoi2, Worawit Louthrenoo3, Laniyati Hamijoyo4, Jiacai Cho5, Aisha Lateef6, Shue-Fen Luo7, Yeong-Jian Wu8, C.S. Lau9, YI-HSING CHEN10, Sandra Navarra11, Leonid Zamora11, Zhanguo Li12, Yuan An12, Sargunan Sockalingam13, Yanjie Hao14, Zhuoli Zhang14, Madelynn Chan15, Yasuhiro Katsumata16, Masayoshi Harigai16, Shereen Oon17, Sang-Cheol Bae18, Sean O’Neill19, Kathryn Gibson19, Jun Kikuchi20, B.M.D.B. Basnayake21, Tsutomu Takeuchi22, Kristine (Pek Ling) Ng23, Fiona Goldblatt24, Annie Law25, Nicola Tugnet26, Yoshiya Tanaka27, Sunil Kumar28, Michael Tee29, Jin Yu Tan30, Chetan Karyekar31, Mandana Nikpour32, Vera Golder1 and Eric Morand33, 1Monash University, Clayton, Australia, 2Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, 3Maharaj Nakorn Chiangmai, Chiang Mai, Thailand, 4University of Padjadjaran, Bandung, Indonesia, 5National University Health System (NUHS), Singapore, Singapore, 6National University Hospital, Singapore, Singapore, 7Chang Gung Memorial Hospital, Taipei, Taiwan, 8Chang Gung Memorial Hospital, Taoyuan County, Taiwan, 9University of Hong Kong, Hong Kong, Hong Kong, 10Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 11University of Santo Tomas Hospital, Manila, Philippines, 12People's Hospital, Peking University Health Science Center, Beijing, China (People's Republic), 13University of Malaya, Kuala Lumpur, Malaysia, 14Peking University First Hospital, Beijing, China (People's Republic), 15Tan Tock Seng Hospital, Singapore, Singapore, 16Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 17Melbourne Health, Parkville, Australia, 18Hanyang University Medical Center, Seoul, Republic of Korea, 19Liverpool Hospital, Sydney, Australia, 20Keio University School of Medicine, Tokyo, Japan, 21Teaching (General) Hospital, Kandy, Sri Lanka, 22Div. Rheumatology, Keio University, Tokyo, Japan, 23North Shore Hospital, Auckland, New Zealand, 24Flinders Medical Centre, Adelaide, Australia, 25Singhealth, Singapore, Singapore, 26Auckland District Health Board, Auckland, New Zealand, 27University of Occupational and Environmental Health, Kitakyushu, Japan, 28Counties Manukau Health, Auckland, New Zealand, 29University of the Philippines, Quezon City, Philippines, 30Janssen Asia Pacific, Singapore, Singapore, 31Janssen R&D, Spring House, PA, 32University of Melbourne at St Vincent's Hospital, Melbourne, Australia, 33School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia

    Background/Purpose: The SLE Responder Index (SRI) is a composite responder definition employed as a clinical trial endpoint in SLE. Despite its widespread adoption, recent discrepant…
  • Abstract Number: 1694 • ACR Convergence 2021

    Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs

    Ronald van Vollenhoven1, Stephen Hall2, Alvin Wells3, Sebastian Meerwein4, Yanna Song5, Jessica Suboticki5 and Roy Fleischmann6, 1Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 2Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, 3Rheumatology and Immunotherapy Center, Franklin, WI, 4AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 5AbbVie Inc., North Chicago, IL, 6Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Sustained clinical remission (REM) is the primary treatment goal for patients with rheumatoid arthritis (RA), with low disease activity (LDA) being an appropriate target…
  • Abstract Number: 1490 • ACR Convergence 2020

    Pain Rating Variability and Response to Treatment in Osteoarthritis Clinical Trials

    Camila Pinto1, Joana Barroso2 and Thomas Schnitzer3, 1Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Department of Physiology, Northwestern University, Feinberg School of Medicine, Chicago, IL, 3Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Despite the known high inter- and intra-patient variability in analgesic responses in chronic pain, most interventional pain studies rely on single time point pain…
  • Abstract Number: 1515 • ACR Convergence 2020

    Renal Responder Status and Associated Clinical Variables in the Lupus Accelerating Medicines Partnership Cohort

    Philip Carlucci1, Andrea Fava2, Kristina Deonaraine1, Jessica Li3, David Wofsy4, Judith James5, Chaim Putterman6, Betty Diamond7, Derek Fine8, Jose Monroy-Trujillo8, Kristin Haag8, William Apruzzese9, H. Michael Belmont10, Peter Izmirly11, Sean Connery12, Fernanda Payan-Schober12, Richard Furie13, Celine Berthier14, Maria Dall'Era15, Kerry Cho16, Diane Kamen17, Kenneth Kalunian18, The Accelerating Medicines Partnership in SLE Network19, Michelle Petri20 and Jill Buyon21, 1New York University School of Medicine, New York, 2Johns Hopkins, Baltimore, 3Johns Hopkins University, Baltimore, MD, 4University of California San Francisco, San Francisco, CA, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Albert Einstein College of Medicine, Bronx, NY, 7Northwell Health, Hartford, 8Johns Hopkins University, Baltimore, 9., Boston, 10NYU School of Medicine, New York, NY, 11Department of Medicine, New York University School of Medicine, New York, NY, 12Texas Tech University Health Sciences Center, Lubbock, 13Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 14University of Michigan, Ann Arbor, 15Division of Rheumatology, University of California, San Francisco, CA, 16University of California San Francisco, San Francisco, 17Medical University of South Carolina, Charleston, SC, 18School of Health Sciences, University of California, La Jolla, 19Multiple Institutions, Multiple Cities, 20Johns Hopkins University School of Medicine, Baltimore, 21Department of Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: Poor therapeutic response rates contribute to the increased morbidity and mortality associated with lupus nephritis. Early identification of patients likely to respond is crucial…
  • Abstract Number: 1516 • ACR Convergence 2020

    The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership

    Philip Carlucci1, Kristina Deonaraine1, Andrea Fava2, Jessica Li3, David Wofsy4, Judith James5, Chaim Putterman6, Betty Diamond7, Derek Fine8, Jose Monroy-Trujillo8, Kristin Haag8, William Apruzzese9, H. Michael Belmont10, Peter Izmirly11, Sean Connery12, Fernanda Payan-Schober12, Richard Furie13, Celine Berthier14, Maria Dall'Era15, Kerry Cho16, Diane Kamen17, Kenneth Kalunian18, The Accelerating Medicines Partnership in SLE Network19, Michelle Petri20 and Jill Buyon21, 1New York University School of Medicine, New York, 2Johns Hopkins, Baltimore, 3Johns Hopkins University, Baltimore, MD, 4University of California San Francisco, San Francisco, CA, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Albert Einstein College of Medicine, Bronx, NY, 7Northwell Health, Hartford, 8Johns Hopkins University, Baltimore, 9., Boston, 10NYU School of Medicine, New York, NY, 11Department of Medicine, New York University School of Medicine, New York, NY, 12Texas Tech University Health Sciences Center, Lubbock, 13Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 14University of Michigan, Ann Arbor, 15Division of Rheumatology, University of California, San Francisco, CA, 16University of California San Francisco, San Francisco, 17Medical University of South Carolina, Charleston, SC, 18School of Health Sciences, University of California, La Jolla, 19Multiple Institutions, Multiple Cities, 20Johns Hopkins University School of Medicine, Baltimore, 21Department of Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: Lupus nephritis continues to be the complication with the highest standardized mortality ratio in Systemic Lupus Erythematosus (SLE), and a late diagnosis associates with…
  • Abstract Number: 1645 • ACR Convergence 2020

    Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program

    Luana Colloca1, Robert Dworkin2, John Farrar3, Leslie Tive4, Ed Whalen5, Jerry Yang4, Lars Viktrup6, Mark Brown7, Christine West7 and Kenneth Verburg8, 1University of Maryland, Baltimore, 2University of Rochester School of Medicine and Dentistry, Rochester, NY, 3University of Pennsylvania, Philadelphia, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc, New York, 6Eli Lilly and Company, Indianapolis, IN, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, Groton

    Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…
  • Abstract Number: 1893 • ACR Convergence 2020

    Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses

    Corinne Miceli-Richard1, Denis Poddubnyy2, Atul Deodhar3, Weibin Bao4, Craig Parman5, Brian Porter6 and Effie Pournara5, 1Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, 2Charité – Universitätsmedizin Berlin, Berlin, Germany, 3Oregon Health & Science University, Portland, OR, 4Novartis Pharmaceuticals Corporation, East Hannover, 5Novartis Pharma AG, Basel, Switzerland, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Predicting outcomes early in the disease course in patients (pts) with ankylosing spondylitis (AS) is challenging, owing to heterogeneity of symptoms, varying disease severity,…
  • Abstract Number: 2031 • ACR Convergence 2020

    Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis

    Augusta Ortolan1, Victoria Navarro-Compán2, Alexandre Sepriano3, Robert Landewé4, Désirée van der Heijde5 and Sofia Ramiro6, 1Leiden University Medical Center, Padova, Italy, 2Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, 3Leiden University Medical Center, Portela Loures, Portugal, 4Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, 5Leiden University Medical Center, Leiden, Netherlands, 6Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: Several disease activity response and status criteria are used to assess treatment efficacy in RCTs in axial spondyloarthritis (axSpA). Response criteria include: the Assessment…
  • Abstract Number: 0200 • ACR Convergence 2020

    Predictors of Durable Clinical Response to Tofacitinib 11 Mg Once Daily with or Without Methotrexate in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Data from a Phase 3b/4 Methotrexate Withdrawal Study

    Kunihiro Yamaoka1, Stanley B Cohen2, Naonobu Sugiyama3, Harry Shi4, Jose L Rivas5, Annette Diehl4 and Josef Smolen6, 1Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, 2Metroplex Clinical Research Center, Dallas, TX, 3Pfizer Japan Inc, Tokyo, Japan, 4Pfizer Inc, Collegeville, PA, 5Pfizer SLU, Madrid, Spain, 6Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria

    Background/Purpose: ORAL Shift, a global Phase 3b/4 non-inferiority study, demonstrated sustained efficacy/safety of tofacitinib modified-release (MR) 11 mg QD following MTX withdrawal in patients (pts)…
  • Abstract Number: 0427 • ACR Convergence 2020

    Validation of Physician Global Assessment as an Outcome Measure in Relapsing Polychondritis

    Emily Rose1, Marcela Ferrada1, Kaitlin Quinn2, Wendy Goodspeed1, Laurent Arnaud3 and Peter C. Grayson4, 1Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, BETHESDA, MD, 2Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, 3Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, Alsace, France, 4Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD

    Background/Purpose: Relapsing polychondritis (RP) is a rare systemic inflammatory disorder of cartilage that lacks validated disease activity measures. Physician global assessment (PhGA) is a measure…
  • Abstract Number: 0480 • ACR Convergence 2020

    Impact of Targeting Remission or Low Disease Activity on 10-year Severity in Rheumatoid Arthritis : Data from ESPOIR Cohort

    Julia Dupont1, Gregory Guernec2, Yannick Degboé3, Frédéric Lioté4, Olivier Vittecoq5, Arnaud Constantin6 and Adeline Ruyssen Witrand7, 1University Hospital of Thoulouse, Toulouse, 2Inserm UMR 1027, TOULOUSE CEDEX 9, France, 3University Hospital of Toulouse, Toulouse, 4AP-HP, Paris, France, 5University Hospital of Rouen, Rouen, France, 6Rheumatology Department, Toulouse University Hospital, Toulouse, France, 7Rheumatology center, University Hospital of Toulouse, Inserm 1027, University Paul Sabatier, Toulouse, France, Toulouse, France

    Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to target remission or at least low disease activity (LDA). We previously showed that SDAI remission…
  • Abstract Number: 0482 • ACR Convergence 2020

    Differential Influence of CDAI Components Based on Disease State in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort

    Edward C Keystone1, Mohammad Movahedi2, Angela Cesta3, Claire Bombardier4, John Sampalis5 and Emmanouil Rampakakis5, 1Mount Sinai Hospital, Toronto, ON, Canada, 2Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 3Toronto General Hospital Research Institute, Toronto, ON, Canada, 4Institute for Work and Health, Toronto, ON, Canada, 5JSS Medical Research, St-Laurent, QC, Canada

    Background/Purpose: Treat-to-target recommendations for rheumatoid arthritis (RA) dictate that remission or low disease activity should be aimed. Although numerous composite indices are available, the clinical…
  • Abstract Number: 0820 • ACR Convergence 2020

    High Remission Rates in RA – Real Life Data from Bariticinib

    Sara Bayat1, Koray Tascilar2, Arnd Kleyer2, David Simon2, Axel Hueber3 and Georg Schett4, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 3Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, 4Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: Recent developments of targeted treatments such as targeted synthetic DMARDs (tsDMARDs) increase the chances of a sustained low disease activity (LDA) or remission state…
  • Abstract Number: 0909 • ACR Convergence 2020

    Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study

    Iain McInnes1, Philip Mease2, Dafna Gladman3, Laura Coates4, Peter Nash5, Alexis Ogdie6, Frank Behrens7, Philippe Goupille8, Arthur Kavanaugh9, Ruvie Martin10, Erhard Quebe-Fehling11 and Corine Gaillez11, 1Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 4University of Oxford, Oxford, United Kingdom, 5School of Medicine Griffith University, Brisbane, Queensland, Australia, 6University of Pennsylvania, Philadelphia, PA, 7CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, 8CHU Tours, department of rheumatology, Tours, France, 9Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ, 11Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Recent EULAR recommendations propose that treatment of psoriatic arthritis (PsA) should seek remission (REM) or alternatively low disease activity (LDA) by regular disease activity…
  • Abstract Number: 1129 • ACR Convergence 2020

    Discordance in Patient and Physician Assessment of Disease Activity in Relapsing Polychondritis

    Emily Rose1, Marcela Ferrada1, Kaitlin Quinn2, Wendy Goodspeed1, Laurent Arnaud3 and Peter C. Grayson4, 1Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, 3Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, Alsace, France, 4Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD

    Background/Purpose: Relapsing polychondritis (RP) is a rare chronic disabling inflammatory condition primarily affecting cartilage tissue. Self-reported patient outcome measures, which have not been evaluated in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology